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Abstract Background
 
Several studies have reported differences in the mortality risk between diabetic
subjects detected by screening and known diabetic patients. We studied mortality in relation to
diabetes duration, and the contribution of other cardiovascular risk factors to the elevated risk.
 
Materials and methods
 
Participants were type 2 diabetic subjects (
 
n
 
 = 174) of a
population-based cohort study. Of these, 95 were diagnosed by screening. Known diabetic
subjects were grouped into two categories of diabetes duration, with a median duration of
2·4 and 11·2 years, respectively. We assessed the contribution of classical cardiovascular risk
factors (dyslipidaemia, hypertension, and prior myocardial infarction), and of new
cardiovascular risk factors (microalbuminuria, von Willebrand factor, sVCAM-1 and C-
reactive protein) to the mortality risk during nearly 10 years of follow up. Cox’s proportional
hazards model was used to study the association of diabetes duration and mortality.
 
Results
 
The age- and sex-adjusted relative risks of mortality were 2·06 (95% C.I. 1·04–
4·10) and 3·19 (1·64–6·20) for the patients with short- and long-term diabetes compared
with the screening-detected diabetic subjects, respectively. Adjustment for cardiovascular risk
factors resulted in a reduction of mortality risk in both groups: 1·13 (0·51–2·50) and 2·39
(1·18–4·83), respectively. Mortality risk significantly increased with increasing diabetes
duration, even after multiple adjustment (
 
P
 
-value for trend ranged from < 0·001–0·018).
 
Conclusions
 
Mortality risk increased with increasing diabetes duration. In subjects with
short diabetes duration the mortality risk could largely be attributed to other risk factors.
In subjects with a longer diabetes duration, however, the elevated mortality risk was
independent of these cardiovascular risk factors.
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Introduction
 
Some longitudinal studies have shown that mortality risk is
higher in known diabetic patients as compared with patients
detected by (population) screening [1,2]. In view of the cur-
rent debate about screening for type 2 diabetes [3], it would
be helpful to know the explanation for this difference in
mortality risk. Difference in diabetes duration seems to be
an obvious candidate, but the results are inconsistent. Data
from the Whitehall Study and the WHO Multinational
Study of Vascular Disease in Diabetes [4,5] failed to show
any relation between diabetes duration and mortality risk.
In contrast, other studies have shown higher mortality risk
for a longer diabetes duration [2,6,7]. In a small Finnish
study, the association was independent of known cardio-
vascular risk factors [2].
Longer diabetes duration is associated with an increased
prevalence of classical cardiovascular risk factors (hyper-
tension, dyslipidaemia, and prevalent heart disease), which
may partly explain the elevated mortality risk. In addition,
a longer duration of diabetes implies longer exposure to
chronic hyperglycaemia, with its deleterious effect on small
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and large vessels [8]. Markers of endothelial dysfunction,
such as microalbuminuria, von Willebrand factor and
soluble vascular adhesion molecule-1, and markers of low-
grade inflammation, like high levels of C-reactive protein,
have been postulated as ‘new’ cardiovascular risk factors [9].
These new risk factors may also partly explain the associ-
ation of diabetes duration with mortality risk.
In view of these considerations, we addressed the ques-
tion of whether diabetes duration is associated with
increased mortality risk, independently of classical and new
cardiovascular risk factors. The question was addressed in
the Hoorn Study, a population-based cohort study of glu-
cose intolerance with a follow up of nearly 10 years.
 
Methods
 
Population
 
The Hoorn Study is a population-based cohort study of
glucose intolerance in a Caucasian population aged 50–75
years. Baseline examinations were conducted from October
1989 until February 1992, as previously described [10]. Briefly,
all 2484 subjects, except previously diagnosed diabetic sub-
jects treated with oral glucose-lowering agents or insulin,
underwent a 75-g oral glucose tolerance test. Subjects with
a 2-h glucose 
 
‡
 
 7·5 mmol L
 
-
 
1
 
, all type 2 diabetic subjects
and a random sample of subjects with a 2-h glucose
< 7·5 mmol L
 
-
 
1
 
 stratified for age and sex were invited for a
second oral glucose tolerance test (OGTT). An extensive
medical examination was performed in an age- and sex-
stratified sample of 631 subjects [11]. The present analyses
were carried out in all diabetic subjects of this sample
(
 
n
 
 = 174). Subjects who were already treated for diabetes (diet,
oral hypoglycaemic agents or insulin) were classified as hav-
ing known diabetes (KDM, 
 
n
 
 = 79). Subjects detected with
diabetes by means of the OGTT were considered to have
screening-detected diabetes mellitus (SDM, 
 
n
 
 = 95). The
WHO diagnostic criteria of 1985 were applied to the mean
fasting and mean 2-h glucose values of the two OGTTs
[12]. All participants gave informed consent for this study,
which was approved by the local Ethics Committee.
 
Measurements
 
Information about the duration and family history of the
diabetes was self-reported and collected by means of a
questionnaire. Duration of diabetes was defined as the time
from diagnosis to study entry. Diabetes duration was not
distributed normally as the duration of all diabetic patients
detected by screening was zero, while the duration in the
group of known diabetic subjects ranged from approxi-
mately 3 months to 29 years. In the known diabetic patients,
the median of diabetes duration (6·2 years) was used as a
cut off to form two groups. One group included known dia-
betic patients with short diabetes duration (median 2·4 and
range 0·3–6·2 years), the other group consisted of patients
with long diabetes duration (median 11·2 and range 6·3–
29·0 years). Family history of diabetes was considered
positive if any of the subject’s grandparents, parents, siblings
or children had a history of diabetes. We obtained data on
blood pressure, weight, height, body mass index (BMI) and
smoking habits, and performed an ECG recording [13,14].
Subjects were considered to have hypertension with dia-
stolic blood pressure 
 
‡
 
 95 mmHg, systolic blood pressure
 
‡
 
 160 mmHg, and/or when using antihypertensive medication
(i.e. the definition in use when baseline data were collected).
Prior myocardial infarction was considered present when
the ECG recording contained Minnesota codes 1·1–1·2.
Current smoking was defined as currently smoking cigarettes
or cigars. We also obtained information about fasting and
2-h plasma glucose, glycated haemoglobin, serum total cho-
lesterol, high-density lipoprotein cholesterol (HDL-cholesterol)
levels and triglycerides [13,14]. High serum total cholesterol
was defined as > 5·0 mmol L
 
-
 
1
 
, low HDL-cholesterol as < 1·0
mmol L
 
-
 
1
 
, elevated LDL-cholesterol as 
 
‡
 
 3·0 mmol L
 
-
 
1
 
 and
high triglycerides as > 2·0 mmol L
 
-
 
1
 
 [15].
Urinary albumin was measured by rate nephelometry
(Array Protein System, Beckman, Galway, Ireland) [11].
Urinary creatinine was measured by a modified Jaffé
method. Subjects were classified as having (micro)albu-
minuria when they had a urinary albumin concentration
above the assay threshold (6·2 mg L
 
-
 
1
 
) and an albumin-to-
creatinine ratio of > 2·0 mg mmol
 
-
 
1
 
 both for the men and
the women [11]. Von Willebrand factor concentrations were
assessed, in duplicate, in heparin plasma by ELISA with
polyclonal antibodies from Dako (Glostrup, Denmark),
and expressed as a percentage of von Willebrand factor in
pooled plasma of the healthy volunteers [16]. Concentrations
of soluble vascular adhesion molecule-1 (sVCAM-1) were
measured, in duplicate, by enzyme-linked immunosorbent
assay kits (Bender MedSystems, Vienna, Austria
[Cat.#BMS232]) as described previously [17]. C-reactive
protein levels (CRP) were assessed, in duplicate, with an
EIA that used rabbit antibodies to C-reactive protein
(Dako) as both the capture and tagging antibody [18]. High
CRP was defined as a level of 2·84 mg L
 
-
 
1
 
 or greater [14].
 
Follow up
 
Data on the subjects’ vital status on January 1st 2001 were
collected from the registry office in the city of Hoorn or else-
where for those who had moved out of Hoorn [1]. For all
participants who died, the cause of death was extracted from
the medical records of the general practitioner and the hos-
pital of Hoorn and classified according to the ninth edition
of the International Classification of Diseases [19]. As a small
number of subjects died of cardiovascular disease (
 
n
 
 = 25),
only all-cause mortality was considered in this paper.
 
Statistical analyses
 
Baseline characteristics were compared between categories
of diabetes duration. For continuous variables we used a test
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for a linear trend within an analysis of variance, adjusted
for age and sex. Logistic regression analysis was used for
binary variables. To study survival, Kaplan–Meier curves
were plotted for the SDM and KDM subjects with diabetes
of short and long duration. Differences in survival were
tested by a log-rank test for linear trends. Cox proportional
hazards multiple regression analyses were used to investig-
ate the association between diabetes duration and mor-
tality. Results are described as relative risks (hazard ratios)
and 95% confidence intervals, with the screening-detected
diabetic patients as the reference group. A test for trend was
used to determine whether mortality risk significantly
increased over the three categories of diabetes duration.
Proportional hazards assumptions were tested with the
inclusion of a time-dependent variable, which showed that
these assumptions were not violated. Variables measured on
a continuous scale were used as such in the regression analyses,
except for triglycerides, total cholesterol, HDL-cholesterol
and CRP-levels, as the association of these variables with
mortality was nonlinear. These variables were dichotomized
according to the cut-off points described earlier.
Selection of variables to be included in the multivariate
analyses was based on the change in estimate approach [20].
All variables that were thought to possibly play a role in the
association between diabetes duration and mortality were
examined in the Cox regression analyses, all adjusted for
age and sex. Those variables that resulted in a change of
the relative risk of mortality associated with diabetes dura-
tion of 10% or more were examined again in the multi-
variate analyses. Only those variables that changed the relative
risk with 10% or more in the multivariate model were
included in the final model. All analyses were performed
with the SPSS for Windows version 10·1·1 software (SPSS
Inc., Chicago, IL, USA). All 
 
P
 
-values were based on two-
sided tests and a 
 
P
 
-value of < 0·05 was considered to be
statistically significant.
 
Results
 
The population consisted of 174 subjects (98 women, 76
men) with a mean age of 66 (
 
–
 
 7) years (Table 1). Treatment
of diabetes in the KDM patients consisted of a diet in 12
subjects, oral hypoglycaemic agents in 52 subjects and insu-
lin in 15 subjects. Fasting plasma glucose and HbA1c levels
Table 1 Baseline characteristics in the categories of diabetes duration
  
Diabetes duration categories SDM
KDM
Short duration Long duration
n 95 40 39
Age (year) 66 (7) 67 (6) 64 (7)
Gender (M/F) 45/50 12/28 19/20
Diabetes duration (year) 0 2·4 (1·3–5·0) 11·2 (7·7–15·9)
Family history of diabetes (%) 37 48 68*
Fasting plasma glucose (mmol L - 1) 8·3 (3·1) 9·7 (3·3) 11·7 (3·7)*
HbA1c (%) 6·7 (1·9) 7·4 (1·6) 8·2 (1·5)*
High total cholesterol (%) 86 90 85
Low HDL-cholesterol (%) 32 28 23
High LDL-cholesterol (%) 89 92 91
High triglycerides (%) 50 46 44
BMI (kg/m*m) 28·8 (4·2) 28·8 (4·9) 28·8 (5·3)
Hypertension (%) 51 63 62
Prior myocardial infarction (%) 1·1 12·5 5·1
Current smoking (%) 23 23 28
Microalbuminuria (%) 10 33 42*
VWF (IU mL- 1) 1·60 (0·80) 1·57 (0·83) 1·77 (0·63)
SVCAM-1 (ng mL - 1) 1442 (458) 1683 (758) 1509 (533)
High CRP (%) 44 42 49
Deaths, n (%) 24 (25) 16 (40) 17 (44)
Data are presented as means (SD), median (interquartile range) (diabetes duration) or percentages.
Diabetes duration categories were defined as subjects with screening-detected diabetes mellitus (SDM), known diabetic patients with 
diabetes duration £  6·2 years (KDM short duration), and known diabetic patients with diabetes duration > 6·2 years (KDM long duration). 
High total cholesterol was defined as serum total cholesterol > 5·0 mmol L - 1; low HDL-cholesterol as HDL < 1·0 mmol L - 1; elevated 
LDL-cholesterol as ‡  3·0 mmol L- 1 and high triglyceride level as > 2·0 mmol L - 1. Hypertension was defined as diastolic blood pressure 
‡  95 mmHg, systolic blood pressure ‡  160 mmHg, and/or use of antihypertensive medication; and prior myocardial infarction as Minnesota 
codes 1·1–1·2 in ECG recording. Family history of diabetes was considered positive if any of the subject’s grandparents, parents, siblings 
or children had a history of diabetes. Current smoking was defined as currently smoking cigarettes or cigars. Microalbuminuria was defined 
as albumin-to-creatinine ratio of > 2·0 mg mmol- 1; and high C-reactive protein (CRP) as CRP > 2·84 mg L- 1. BMI, body mass index; VWF, 
von Willebrand factor; sVCAM-1, soluble vascular adhesion molecule-1.
*P-value for trend < 0·05.
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increased with diabetes duration, and were highest in the
long diabetes duration group. Family history of diabetes
and (micro)albuminuria also showed a significant trend over
categories of diabetes duration. The prevalence of prior
myocardial infarction was highest in the short diabetes
duration group as were sVCAM-1 levels. During nearly 10
years of follow up, 57 (33%) subjects died. Among the SDM
subjects, 25% died compared with 40% and 44% in the
groups of short and long diabetes duration, respectively.
Figure 1 shows the Kaplan–Meier survival curves for
categories of diabetes duration. Mortality significantly
increased with a longer diabetes duration (log-rank test for
linear trend, 
 
c
 
2
 
 = 5·23, 
 
P
 
-value = 0·02). Testing of cardio-
vascular risk factors showed that microalbuminuria, prior
myocardial infarction, sVCAM-1 levels and family history
of diabetes changed the relative risk of diabetes duration
with more than 10% in the Cox regression analyses. Other
risk factors did not result in a 10% change and were not
included in the multiple regression models.
Table 2 shows the results of the multivariate survival
analyses. Mortality risk increased with increasing diabetes
duration (model 1) and this effect was also observed after
adjustment for various cardiovascular risk factors and family
history of diabetes (models 2–5). Simultaneous adjustment
for (micro)albuminuria, prior myocardial infarction and
sVCAM-1 resulted in a reduction of relative risk in both
categories of diabetes duration (model 6). The risk estimate
in the group with long diabetes duration was reduced, but
remained elevated. Additional adjustment for family history
of diabetes (model 7) resulted in an increase in relative risk
(1·18 and 2·92, respectively). The increase in mortality risk
with increased diabetes duration showed a statistically sig-
nificant trend in all models.
We investigated whether the definition of the diabetes
duration groups affected the results. When the diabetes
duration was divided into tertiles and the screening-
detected diabetic patients were used as a reference group,
the association between diabetes duration and mortality also
showed a significant trend. This significant trend was also
present after multiple adjustment (data not shown).
 
Discussion
 
This study shows that mortality risk rises with increasing
diabetes duration. In the diabetic subjects with long
diabetes duration the association with mortality risk was
independent of cardiovascular risk factors. However, in the
subjects with short diabetes duration, the association could
largely be attributed to cardiovascular risk factors.
Diabetes duration since diagnosis, the variable of princi-
pal interest in this study, is clearly an underestimation of
the actual duration of the disease, because a diagnosis is
never made at the actual start of hyperglycaemia in the dia-
betic range. Patients detected by screening may be nearer
the true onset of diabetic hyperglycaemia as they are asymp-
tomatic at the time of the diagnosis. In known diabetic
patients, who do present with symptoms and signs at diag-
nosis, this underestimation of the diabetes duration might
be worse.
The lower risk in the SDM subjects may also partly be
explained by length-time bias associated with screening
[21]. Length-time bias means that those with a more serious
type of diabetes will present with symptoms and signs and
will be detected accordingly, independent of screening. In
the remaining population at risk for diabetes, people with
a relatively mild form of diabetes with a slower progression
and better prognosis are over-represented, and will be
detected by screening. This way, mortality risk in patients
with screening-detected diabetes mellitus might be lower,
not because of the shorter diabetes duration, but because
they have a more ‘benign’ type of diabetes. On the other
hand, after adjustment for cardiovascular risk factors,
known diabetic patients with short duration had a mortality
risk similar to that of screening-detected diabetic patients,
a result that does not seem to support the ‘benign type of
diabetes explanation.
Population size and the relatively small number of events
in this study restricted the number of variables that could
be included in the Cox regression models. Therefore, other
risk factors that might play a role in the association between
diabetes duration and mortality might have been missed.
In addition, factors that were not measured in our study
such as small dense LDL particles might explain part of the
association.
The lower prevalence of high cholesterol levels and low
HDL-cholesterol and sVCAM-1 levels and prior myocar-
dial infarction in the group with long diabetes duration
might be indicative of a ‘healthy survivor effect’. Subjects
with diabetes and multiple risk factors for heart disease have
a high risk of having already died, before reaching old age
Figure 1 Survival (Kaplan–Meier) curves according to categories 
of diabetes duration. SDM, screening-detected diabetic patients; 
KDM, short duration: known diabetic patients with duration 
£  6·2 years; KDM, long duration: known diabetic patients with 
duration > 6·2 years.
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and a longer diabetes duration. However, if this healthy
survivor effect were present, a relatively low mortality risk in
the survivors would be expected. But this was not observed,
and despite the possibility of this healthy survivor effect we
found the association between mortality and long diabetes
duration to be statistically independent of other risk factors.
The results of our study are in line with some
[2,6,7,22,23] but not all published studies [4,5] concerning
the association between diabetes duration and mortality.
All previous studies differed in one or more of the following
aspects from our study: end-point (CHD vs. all-cause) [2],
duration of follow up [2,4,6,7,22,23], age-distribution [2,4–
7,22,23] and sex-distribution [4,22] of the population. In
most other studies, diabetes duration was divided into cat-
egories of 5 years of duration and newly diagnosed subjects
were included in the category with the shortest duration
(< 5 years) [2,6,7,22]. In these studies the diagnosis of dia-
betes was based on one OGTT [2,23] or patients were diag-
nosed by their general practitioner [6,7]. In contrast, in our
study, the analyses were performed with the SDM subjects
as the reference category, and thus resulted in more precise
estimates of mortality risk in diabetic subjects with short
diabetes duration. Moreover, the diagnosis of diabetes was
based on the mean of two OGTTs, reducing random mis-
classification as a result of variable glucose levels.
This study is the first prospective study to address the
association of diabetes duration with mortality risk not only
in the context of classical risk factors but also in the context
of new risk factors indicative of endothelial dysfunction or
low-grade inflammation. In our study, higher mortality in
the short duration group was explained completely by prior
myocardial infarction, microalbuminuria and levels of
sVCAM-1, but only partly in the group with long diabetes
duration. Prior myocardial infarction is a well-known risk
factor for mortality in diabetic and nondiabetic individuals
[24]. Microalbuminuria also has a well-established association
with mortality [25]. Elevated levels of sVCAM-1 have been
suggested to reflect the progressive formation of atheroscle-
rotic lesions [26] and to be associated with symptomatic
atherosclerotic disease in type 2 diabetic patients [27]. In
the Hoorn Study sVCAM-1 was associated with cardio-
vascular and all-cause mortality independent of other risk
factors [17].
Adjustment for family history of diabetes resulted in a
higher relative risk, particularly in individuals with long
diabetes duration. This effect might be explained by the fact
that people with a positive family history are more carefully
monitored for diabetes and are diagnosed earlier, and there-
fore selectively have, on average, longer diabetes duration
than patients without a family history. Consequently, after
correction, the association of actual diabetes duration with
mortality risk is even stronger.
Our results suggest a continuously increasing mortality
risk with increasing diabetes duration independent of other
risk factors. The underlying pathophysiological mechanism
is as yet unclear. Diabetes duration might be a marker of
duration of exposure to chronic hyperglycaemia. In this
view, the fact that long diabetes duration is an independ-
ent risk factor might be reflective of the irreversibility of
hyperglycaemia-induced changes in cardiovascular structure
and function. This irreversibility has been shown by the
observation in some studies, that improved glycaemic control
(decrease in HbA1c) does not decrease the concentration
of endothelial markers nor haemostatic abnormalities in
type 2 diabetic patients [28,29].
In our view, the results of this study indicate either that
diabetes duration per se is a strong and independent
risk factor for mortality in type 2 diabetic patients or that
diabetes duration is reflective of other, yet unknown, potent
risk factors. Larger studies are needed to study the
Table 2 Relative risks (95% confidence intervals) for categories of diabetes duration relative to the subjects with screening-detected diabetes 
mellitus
  
  
Cox regression models 
(SDM, reference group: n = 90, 21 events)*
Relative risk (95% CI) 
P-value 
for trend†
KDM: short duration 
(n = 36, 14 events)*
KDM: long duration
(n = 37, 17 events)*
Model 1: age and sex 2·06 (1·04–4·10) 3·19 (1·64–6·20) < 0·001
Model 2: model 1 + microalbuminuria 1·79 (0·88–3·67) 2·66 (1·30–5·41)  0·006
Model 3: model 1 + prior myocardial infarction 1·68 (0·82–3·46) 3·03 (1·56–5·92)  0·001
Model 4: model 1 + sVCAM-1 1·69 (0·83–3·43) 2·94 (1·51–5·71)  0·001
Model 5: model 1 + family history diabetes 2·18 (1·09–4·37) 4·25 (2·07–8·71) < 0·001
Model 6: model 1 + microalbuminuria + prior MI + sVCAM-1 1·13 (0·51–2·50) 2·39 (1·18–4·83)  0·018
Model 7: model 6 + family history of diabetes 1·18 (0·53–2·64) 2·92 (1·36–6·27)  0·008
Diabetes duration categories were defined as subjects with screening-detected diabetes mellitus (SDM), known diabetic patients with 
diabetes duration £  6·2 years (short duration KDM), and known diabetic patients with diabetes duration over 6·2 years (long duration 
KDM).
Prior myocardial infarction (prior MI) was defined as Minnesota codes 1·1–1·2 in ECG recording. Family history of diabetes was 
considered positive if any of the subject’s grandparents, parents, siblings or children had a history of diabetes. Microalbuminuria was 
defined as albumin-to-creatinine ratio of > 2·0 mg mmol - 1. sVCAM-1, soluble vascular adhesion molecule-1.
*Numbers and events reduced because of missing data for some variables included in the analyses.
†To test whether mortality risk significantly increased over the three categories of diabetes duration.
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pathophysiological mechanisms underlying the associa-
tion of diabetes duration and elevated mortality. Other
studies will show whether early treatment of hyperglycaemia
and cardiovascular risk factors in screening-detected dia-
betic patients will have any impact on mortality risk.
In conclusion, mortality risk was elevated in the known
diabetic patients compared with the screened subjects. Mor-
tality risk associated with diabetes duration was independ-
ent of risk factors in the diabetic patients with long duration.
In the patients with short duration, the elevated mortality
risk associated with diabetes duration could for the most
part be attributed to cardiovascular risk factors. These
results emphasize the importance of treating cardiovascular
risk factors in type 2 diabetic patients.
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